Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: The PASSPORT Program - Asia-Pacific Region

International Journal of Antimicrobial Agents

Volumn 37, Issue 3, 2011, Pages 225-229

  Roberts, Jason A ^a   Kwa, Andrea ^b   Montakantikul, Preecha ^c   Gomersall, Charles ^d   Kuti, Joseph L ^e   Nicolau, David P ^e  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c MAHIDOL UNIVERSITY   (Thailand)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e HARTFORD HOSPITAL   (United States)

Author keywords

Carbapenem; Doripenem; Imipenem; Meropenem; Pharmacodynamics; Resistance

Indexed keywords

CARBAPENEM; CILASTATIN PLUS IMIPENEM; DORIPENEM; MEROPENEM;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; ASIA; BACTERIAL COUNT; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG MEGADOSE; DRUG SCREENING; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; INTRAVENOUS ADMINISTRATION; KIDNEY FUNCTION; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; ASIA; AUSTRALIA; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; IMIPENEM; INJECTIONS, INTRAVENOUS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; THIENAMYCINS;

EID: 79951945968     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.10.024     Document Type: Article

References (31)

1. J.J. Rahal Antimicrobial resistance among and therapeutic options against Gram-negative pathogens Clin Infect Dis 49 Suppl. 1 2009 S4 S10
2. H.W. Boucher, G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert, and L.B. Rice Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America Clin Infect Dis 48 2009 1 12
3. J.L. Vincent, J. Rello, J. Marshall, E. Silva, A. Anzueto, and C.D. Martin International study of the prevalence and outcomes of infection in intensive care units JAMA 302 2009 2323 2329
4. J.A. Karlwosky, D.C. Draghi, M.E. Jones, C. Thornsberry, I.R. Friedland, and D.F. Sahm Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001 Antimicrob Agents Chemother 47 2003 1681 1688 (Pubitemid 36548554)
5. M.M. Neuhauser, R.A. Weinstein, R. Rydman, L.H. Danziger, G. Karam, and J.P. Quinn Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use JAMA 289 2003 885 888 (Pubitemid 37430348)
6. H. Wisplinghoff, T. Bischoff, S.M. Tallent, H. Seifert, R.P. Wenzel, and M.B. Edmond Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study Clin Infect Dis 39 2004 309 317 (Pubitemid 39050477)
7. P.R. Rhomberg, and R.N. Jones Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America Diagn Microbiol Infect Dis 47 2003 365 372 (Pubitemid 37101171)
8. R.R. Reinert, D.E. Low, F. Rossi, X. Zhang, C. Wattal, and M.J. Dowzicky Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline J Antimicrob Chemother 60 2007 1018 1029 (Pubitemid 47617749)
9. S.P. Hawser, S.K. Bouchillon, D.J. Hoban, R.E. Badal, P.R. Hsueh, and D.L. Paterson Emergence of high levels of extended-spectrum-β-lactamase- producing Gram-negative bacilli in the Asia-Pacific Region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program, 2007 Antimicrob Agents Chemother 53 2009 3280 3284
10. G.L. Drusano Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' Nat Rev Microbiol 2 2004 289 300 (Pubitemid 39490099)
11. C.R.V. Kiffer, C. Mendes, J.L. Kuti, and D.P. Nicolau Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa from the MYSTIC Surveillance Program: the OPTAMA Program, South America 2002 Diagn Microbiol Infect Dis 49 2004 109 116 (Pubitemid 38746740)
12. J.L. Kuti, C.H. Nightingale, and D.P. Nicolau Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002 Antimicrob Agents Chemother 48 2004 2464 2470 (Pubitemid 38823411)
13. R.G. Masterton, J.L. Kuti, P.J. Turner, and D.P. Nicolau The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe J Antimicrob Chemother 55 2005 71 77 (Pubitemid 40192616)
14. C.A. DeRyke, J.L. Kuti, and D.P. Nicolau Pharmacodynamic target attainment of six β-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004 Pharmacotherapy 27 2007 333 342 (Pubitemid 46327901)
15. P. Koomanachai, J.L. Crandon, J.L. Kuti, and D.P. Nicolau Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program Int J Antimicrob Agents 33 2009 348 353
16. J.L. Crandon, J.L. Kuti, R.N. Jones, and D.P. Nicolau Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on Gram-negative resistance Ann Pharmacother 43 2009 220 227
17. P. Koomanachai, C.C. Bulik, J.L. Kuti, and D.P. Nicolau Pharmacodynamic modeling of intravenous antibiotics against Gram-negative bacteria collected in the United States Clin Ther 32 2010 766 779
18. K. Ikawa, N. Morikawa, S. Uehara, K. Monden, Y. Yamada, and N. Honda Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients Int J Antimicrob Agents 33 2009 276 279
19. S.G. Sakka, A.K. Glauner, J.B. Bulitta, M. Kinzig-Schippers, W. Pfister, and G.L. Drusano Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized controlled trial Antimicrob Agents Chemother 51 2007 3304 3310 (Pubitemid 350067544)
20. Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau DP. Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med Forthcoming.
21. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twentieth information supplement. Document M100-S20-U. Wayne, PA: CLSI; 2010.
22. DORIBAX® (doripenem for infection) prescribing information. Raritan, NJ: Ortho-McNeil. http://www.doribax.com/doribax/shared/pi/doribax.pdf. [accessed 19 July 2010].
23. E. Lautenbach, and R.E. Polk Resistant Gram-negative bacilli: a neglected healthcare crisis? Am J Health Syst Pharm 64 Suppl. 14 2007 S3 S21
24. J.L. Kuti, and D.P. Nicolau Making the most of surveillance studies: summary of the OPTAMA program Diagn Microbiol Infect Dis 53 2005 281 287 (Pubitemid 41796899)
25. R.N. Jones, H.S. Sader, and T.R. Fritsche Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various β-lactamase resistance mechanisms Diagn Microbiol Infect Dis 52 2005 71 74 (Pubitemid 40692744)
26. D.L. Paterson, W.C. Ko, A. Von Gottberg, S. Mohapatra, J.M. Casellas, and H. Goossens Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases Clin Infect Dis 39 2004 31 37 (Pubitemid 38879546)
27. K. Kaniga, R. Flamm, S.Y. Tong, M. Lee, I. Friedland, and R. Redman Worldwide experience with the use of doripenem against extended-spectrum-β- lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies Antimicrob Agents Chemother 54 2010 2119 2124
28. C.C. Bulik, R. Quintiliani Jr., J.S. Pope, J.L. Kuti, and D.P. Nicolau Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis - a review of 3 cases Respir Med CME 3 2010 146 149
29. OXA-23 carbapenemase gene of Acinetobacter baumannii Emerg Infect Dis 16 2010 35 40
30. J.L. Crandon, C.C. Bulik, and D.P. Nicolau In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa Antimicrob Agents Chemother 53 2009 4352 4356
31. D.P. Nicolau Carbapenems: a potent class of antibiotics Expert Opin Pharmacother 9 2008 23 37 (Pubitemid 351233746)